

History

Company History

1890
 Founder Kenkichi Taguchi opens Taguchi Santendo in Kitahama, Osaka

1925
 Operations incorporated as Santendo Co., Ltd.

1935
 Yodogawa Plant established in Higashiyodogawa-ku, Osaka

1944
 Head Office transferred to Yodogawa Plant (current site)

1945
 Company name changed to Santendo Pharmaceutical Co., Ltd.

1958
 Company name changed to current form of Santen Pharmaceutical Co., Ltd.

Santen enters prescription pharmaceutical business

1977
 Stock listed on First Section of Tokyo Stock Exchange and Osaka Securities Exchange

Production system introduced to allow filling of solution into molded containers to make bottle-packed eye drops

1982
 Central Research Laboratories established

1985
 Noto Plant established

1990
 Long-term business vision formulated to mark centenary

1993
 Subsidiary Santen Inc. established in the U.S.

1994
 Subsidiary Santen GmbH established in Germany

1996
 Representative office established in Beijing, China

Nara Research and Development Center and Shiga Plant established

1997
 Finnish ophthalmics pharmaceutical company acquired and Santen Oy established

Subsidiary Taiwan Santen Pharmaceutical Co., Ltd. established

1900

1990

Product History

1890s
 Main product is *Heburin-gan*, a cold medicine



1899
 Launch of *Daigaku Eye Drops*




1952
 Launch of *Daigaku Penicillin Eye Drops*

1953
 Launch of *Daigaku Mycillin Eye Drops*

1954
 Launch of *Daigaku Super Eye Drops*

1956
 Launch of *Sante de U*

1962
 Launch of *Mydrin-P*, a mydriatic drug (for pupil dilation)



Launch of *Super Sante* marks first use of plastic eye drop containers in Japan



1963
 Launch of *Thiola*, an original liver detoxification agent



1970
 Launch of antibiotic ophthalmic *Ecolicin*

1975
 Launch of anti-inflammatory ophthalmic *Flumetholon*

1978
 Santen commences sales of medical devices

1981
 Launch of *Timoptol*, a treatment for glaucoma and ocular hypertension

1985
 Launch of *Sante 40 NE*



1986
 Santen commences sales of intraocular lenses

1987
 Launch of anti-rheumatic *Rimatil*



Launch of anti-infective ophthalmic *Tarivid*



1991
 Launch of *Sante FX*



1992
 Launch of *BSS PLUS*, an ophthalmic perfusion and bathing solution

Launch of *Kary Uni*, a treatment for early-stage senile cataracts



1995
 Launch of *Hyalein*, a treatment for corneal and conjunctival epithelial disorders



Launch of anti-allergy ophthalmic *Alegysal*

Launch of anti-rheumatic *Azulfidine EN*



Launch of *Opegan Hi*, an adjuvant for ophthalmic operations

Note: Based on the years when sales were launched by Santen Pharmaceutical.

1998

Medium-term Plan "Hitomi 21" formulated

2000

Subsidiary Santen Pharmaceutical Korea Co., Ltd. established

Representative office established in Guangzhou, China

2001

U.S.-based Advanced Vision Science, Inc. acquired

2002

Introduced Dimple Bottle, an innovative patient-oriented container for ophthalmic solutions

2003

2003-2005 Medium-Term Management Plan formulated

ISO 14001 certification acquired by Noto Plant

Santen Activity Improved Navigator (SAIN) medical information support system developed

2000

1999

Launch of *Timoptol XE*, a treatment for glaucoma and ocular hypertension

Launch of *Sante FX Neo*

2000

Launch of anti-infective ophthalmic *Cravit*



2001

Launch of *Detantol*, a treatment for glaucoma and ocular hypertension



Launch of anti-allergy ophthalmic *Livostin*



2002

Launch of *Sante de U Plus E Alpha*

Launch of *Sante 40*

2003

Launch of *ClariFlex* foldable intraocular lenses

2004

U.S. sales partnership with Johnson & Johnson Vision Care, Inc. (currently: VISTAKON Pharmaceuticals, LLC) started

2005

Representative office established in Shanghai, China

Subsidiary Santen Pharmaceutical (China) Co., Ltd. established

2006

2006-2010 Medium-Term Management Plan formulated

2007

Representative office established in Shenyang, China

Santen Pharmaceutical (China) Co., Ltd. established Suzhou Plant

2008

Completion of pharmaceutical development building and ancillary building at Nara Research and Development Center

2010

2009

Santen Pharmaceutical (China) Co., Ltd. commenced direct marketing

2010

Santen Pharmaceutical Korea Co., Ltd. commenced direct marketing

2011

2011-2013 Medium-Term Management Plan formulated

Subsidiary Santen India Private Limited established in India

2004

Launch of *Rescula*, a treatment for glaucoma and ocular hypertension

Launch of anti-rheumatic *Metolate*

2006

Launch of *Papilock Mini*, a treatment for vernal keratoconjunctivitis

Launch of *Sante Medical 10*



Launch of *Sante AL Cool II*

2007

Launch of *Sante Uruoi Contact a*

2008

Launch of nutritional supplement *Sante Lutax*

Launch of *Sante 40i*



Launch of *Eternity* foldable intraocular lens



Launch of *Tapros*, a treatment for glaucoma and ocular hypertension



2009

Launch of *Sante FX V Plus*



Launch of *Eternity Natural* foldable intraocular lens

2010

Launch of *Cosopt*, a treatment for glaucoma and ocular hypertension

Launch of *Diquas*, a treatment for dry eye

